.Attributes Medicine, Posted online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA authorization after an adverse test, which highlights the numerous complexities and also obstacles of drug progression in this particular setting.